Bausch + Lomb CEO Brent Saunders Steps Down; Chairman Thomas Appio Named Interim Chief

Bausch + Lomb has announced the departure of Chief Executive Officer (CEO) Brent Saunders by mutual agreement with its Board. Chairman Thomas Appio has been appointed interim CEO with immediate effect, while continuing to lead Bausch Health, which owns approximately 87% of the eye-care company.

The leadership change comes as investors monitor Bausch Health’s plans for its stake in Bausch + Lomb.

Brent Saunders is an experienced healthcare executive and Board leader with a career spanning pharmaceutical, eye care, consumer healthcare and biotechnology. He served as Chairman and CEO of Bausch + Lomb from March 2023 to October 2026, having previously led the company from 2010 to 2013. He was also Chairman, President and CEO of Allergan from 2015 to 2020. Earlier, he held leadership positions at Actavis, Forest Laboratories and Schering-Plough. Saunders currently serves on the Boards of several companies, including Arena, Cambrian Bio and BeautyHealth, where he is Chairman. He also brings board-level experience from Cisco and BridgeBio.

a

Magazine made for you.